{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "CDC_Influenza_vaccines",
  "verification_stats": {
    "total_extracted": 1,
    "verified": 0,
    "rejected": 1,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent (Sanofi Pasteur) 0.5 mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM ... RIV4 (recombinant HA vaccine)",
      "reason": "does not support claim",
      "original_explanation": "This quote identifies Flublok Quadrivalent as a recombinant HA vaccine, which is relevant because recombinant technology is the focus of the claim. It establishes the presence of a recombinant vaccine in the document, which is necessary context for discussing its immune response characteristics."
    }
  ],
  "model_used": "gpt-4.1"
}